152 related articles for article (PubMed ID: 10967121)
1. Role for nucleolin/Nsr1 in the cellular localization of topoisomerase I.
Edwards TK; Saleem A; Shaman JA; Dennis T; Gerigk C; Oliveros E; Gartenberg MR; Rubin EH
J Biol Chem; 2000 Nov; 275(46):36181-8. PubMed ID: 10967121
[TBL] [Abstract][Full Text] [Related]
2. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
Nitiss JL; Nitiss KC
Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
[No Abstract] [Full Text] [Related]
3. Yeast NSR1 protein that has structural similarity to mammalian nucleolin is involved in pre-rRNA processing.
Kondo K; Inouye M
J Biol Chem; 1992 Aug; 267(23):16252-8. PubMed ID: 1644811
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
5. Multiple regions of NSR1 are sufficient for accumulation of a fusion protein within the nucleolus.
Yan C; Mélèse T
J Cell Biol; 1993 Dec; 123(5):1081-91. PubMed ID: 8245119
[TBL] [Abstract][Full Text] [Related]
6. Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.
Woo MH; Vance JR; Bjornsti MA
Methods Mol Biol; 2001; 95():303-13. PubMed ID: 11089242
[No Abstract] [Full Text] [Related]
7. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
8. The amino terminus of mammalian nucleolin specifically recognizes SV40 T-antigen type nuclear localization sequences.
Xue Z; Shan X; Lapeyre B; Mélèse T
Eur J Cell Biol; 1993 Oct; 62(1):13-21. PubMed ID: 8269971
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.
Wright CM; van der Merwe M; DeBrot AH; Bjornsti MA
J Biol Chem; 2015 May; 290(19):12068-78. PubMed ID: 25795777
[TBL] [Abstract][Full Text] [Related]
10. NSR1 is required for pre-rRNA processing and for the proper maintenance of steady-state levels of ribosomal subunits.
Lee WC; Zabetakis D; Mélèse T
Mol Cell Biol; 1992 Sep; 12(9):3865-71. PubMed ID: 1508189
[TBL] [Abstract][Full Text] [Related]
11. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of the genes for two topoisomerase I-interacting proteins from Saccharomyces cerevisiae.
Park H; Sternglanz R
Yeast; 1999 Jan; 15(1):35-41. PubMed ID: 10028183
[TBL] [Abstract][Full Text] [Related]
13. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
15. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
16. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
Eng WK; Faucette L; Johnson RK; Sternglanz R
Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss J; Wang JC
Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7501-5. PubMed ID: 2845409
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Nitiss JL; Wang JC
Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
[TBL] [Abstract][Full Text] [Related]
19. A 26 kDa yeast DNA topoisomerase I fragment: crystallographic structure and mechanistic implications.
Lue N; Sharma A; Mondragón A; Wang JC
Structure; 1995 Dec; 3(12):1315-22. PubMed ID: 8747458
[TBL] [Abstract][Full Text] [Related]
20. Enhanced CPT sensitivity of yeast cells and selective relaxation of Ga14 motif-containing DNA by novel Gal4-topoisomerase I fusion proteins.
Alessandri M; Beretta GL; Ferretti E; Mancia A; Khobta A; Capranico G
J Mol Biol; 2004 Mar; 337(2):295-305. PubMed ID: 15003448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
